The company is a clinical-stage oncology therapeutics company developing next-generation antibody-drug conjugates (ADCs) that combine advanced bioconjugation technology with Topoisomerase I inhibitor payloads to treat validated tumor targets. The company holds global development and commercialization rights to a portfolio of three ADCs targeting PTK7, MUC16, and SEZ6 antigens in cancers including non-small cell lung cancer, ovarian cancer, and neuroendocrine tumors, with the first two programs in Phase 1 clinical trials. The company generates revenue through partnerships and strategic licensing, operates under an outsourced manufacturing and development model with contract research organizations, and benefits from patent protection extending to 2046 or later.